Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. - Wikidata - wikimedia - TriplyDB

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

http://www.wikidata.org/entity/Q45184443

about

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Biomarkers for determining the prognosis in chronic myelogenous leukemia The role of observational studies in optimizing the clinical management of chronic myeloid leukemia Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group.BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients The choice of first-line chronic myelogenous leukemia treatment.How we will treat chronic myeloid leukemia in 2016.Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.Milestones and monitoring.Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia.Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Trial watch: Prognostic and predictive value of the immune infiltrate in cancer Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.Re-emergence of interferon-α in the treatment of chronic myeloid leukemia Pediatric chronic myeloid leukemia is a unique disease that requires a different approach European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.How I treat newly diagnosed chronic phase CML Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern India.

P2860

Q26738514-7D97B516-81F3-4033-A8E4-FD41071A8752 Q26824660-501A490E-C5F0-4481-ADF4-6A5EEA2AF03F Q28085149-4C5712BC-E148-4144-80C5-B4E2B2B77B6C Q30242015-64F741E5-0000-47E2-8F44-2FCF4A83D0E0 Q30491107-170B5F02-FF56-4DCF-B272-6654E0CBFD33 Q30891587-5F3BBDA4-2D6D-4321-8DEA-8EA21EE86A88 Q33166364-A94E20AC-6EB4-4D4E-8304-4802C55A2489 Q33574738-2366A4F5-EF72-449D-A9E6-F14AB2B85361 Q33729437-CED2681D-D81E-48F2-92F9-DF54F4FEFB4F Q33747763-B046492A-CB0F-4A35-AFBE-A14429C4904D Q34521001-38BD35B1-4B9D-44B6-B59F-F3C1E9479124 Q34576982-DEA97A2F-01E2-44B0-8EDC-71F0790F013E Q34642865-CA784723-5F5D-4306-9232-7241744E7A53 Q35051720-9E6251A2-2782-4D32-AD77-877C038C455E Q35221071-A98D46FB-52A6-4314-BE8D-DF6A4B402443 Q35269378-C778EEAA-62E6-4BE7-BE6D-BCDE20B8DA22 Q35560018-833B99E1-0194-47F1-A167-445869C00675 Q35652844-75069AAB-28A7-4318-8DB8-392CEFC25B32 Q35666534-D75564D4-0930-4CF5-A09F-0975BE5E81E8 Q35674595-D937D723-EF4A-4CEC-B9A5-717CC43E078A Q35928884-7BC3A49B-D545-482B-94F5-6AB879507B1E Q35995232-EB254227-16D8-48B2-BE8A-9F809B465AF9 Q36068354-080EBDC9-3B40-4EFF-8E9C-C1058CC6963B Q36070796-45256FA5-B872-4F79-8FD4-CD31A6936E03 Q36094702-27C532C6-6C8D-4866-9DF6-82B364053C9B Q36237990-F8A583F3-7DD5-4692-B1E0-28773459B1A2 Q36263943-FCF0FD02-DE96-458F-BE35-497B92F219AC Q36442499-6A1A396A-154D-4516-9E43-5BEAB8B2D0D0 Q36456483-E4A9C022-D304-480C-89D9-108E33623E20 Q36478229-6B993E10-07B9-4051-944D-D9031636F9F6 Q36708942-D3DDC5DA-D4BB-4EA5-A2E9-091FC7DD1BEC Q36974374-7D13BCCD-4BEC-405B-86F0-192B61DD7B7C Q36989407-29A02156-8E06-4A7C-B56E-0CFDEB48C8A5 Q37025981-AAB6ECAA-FB64-4E2E-BE33-8649D1466C57 Q37026032-B85AEBD1-8E60-43B2-A8FF-10A204C9F0AF Q37027767-5B12DB7C-DD5A-4F2F-B044-A8CFF4187450 Q37098856-5907A807-BD67-43FC-82C0-96D3DC9B8635 Q37144877-79373614-0D74-45B9-B2CA-05C3B9B18A27 Q37366701-EDD606B0-949F-4BE8-A8A3-F363BAB02E3F Q37404680-ED556DD5-C9C8-4C59-B422-BDC0F0C79422

P2860

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

http://www.wikidata.org/entity/Q45184443

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Predicting complete cytogeneti ...... ib treatment: the EUTOS score.

@en

Predicting complete cytogeneti ...... ib treatment: the EUTOS score.

@nl

type

label

Predicting complete cytogeneti ...... ib treatment: the EUTOS score.

@en

Predicting complete cytogeneti ...... ib treatment: the EUTOS score.

@nl

prefLabel

Predicting complete cytogeneti ...... ib treatment: the EUTOS score.

@en

Predicting complete cytogeneti ...... ib treatment: the EUTOS score.

@nl

P1433

Q45184443-0C0CA06E-3C35-4A77-8E27-AE3904E21920

P1476

Q45184443-49B91E4E-712B-4EAC-9389-4AE7B175CC8E

P2093

Q45184443-0D1B1248-A7C5-4584-834C-9C8D2857D8F6

Q45184443-31F89727-E13A-4D03-9D46-B399023CEA74

Q45184443-3A7177E7-4B61-4DC0-B737-4D589AF8C53E

Q45184443-5B90B801-9EE8-4D52-A621-E977355ED774

Q45184443-71C24318-C011-4B13-B06E-6C56A2F626B5

Q45184443-8E819843-8771-4CBE-95C2-0A929B9507E9

Q45184443-944A45BA-BDD0-4313-9088-66920FD57CF3

Q45184443-B3099BB8-6492-419F-8A1C-5376C60CE6FD

Q45184443-BB272C4D-8470-4AF1-AF99-376861DE59F1

Q45184443-BC110446-F98C-4439-B59C-02A8C8388AE5

P304

Q45184443-0FB2B3E6-C609-4B77-9CD1-A6651AD19BF5

P31

Q45184443-60C9365C-85B9-43BC-AED5-5A99A0DF589C

P356

Q45184443-F4AF952F-8854-4757-9AF8-7ED213CE880A

P407

Q45184443-6120D79C-12DC-4531-8FCC-EB150E2E88FF

P433

Q45184443-F0BBA6DD-9235-4F42-9021-58DC67BD5A4A

P478

Q45184443-DF094CE1-039D-4145-9FD9-EEB1CC29385D

P50

Q45184443-8CF4B85C-D381-45EB-BA3B-854BA7DBC59F

Q45184443-DD5D3B9A-5440-4901-B768-20A5342DD212

P577

Q45184443-67BCEE52-647B-43B1-A5FF-149AB30DCACF

P698

Q45184443-62BFBAEF-8B86-47D3-A81C-FAEE180A76B9

P356

BLOOD-2010-12-319038

P1433

P1476

Predicting complete cytogeneti ...... ib treatment: the EUTOS score.

@en

P2093

Bengt Simonsson

http://www.w3.org/2001/XMLSchema#string

Doris Lindoerfer

http://www.w3.org/2001/XMLSchema#string

François Guilhot

http://www.w3.org/2001/XMLSchema#string

Gert Ossenkoppele

http://www.w3.org/2001/XMLSchema#string

Joelle Guilhot

http://www.w3.org/2001/XMLSchema#string

Joerg Hasford

http://www.w3.org/2001/XMLSchema#string

Kimmo Porkka

http://www.w3.org/2001/XMLSchema#string

Markus Pfirrmann

http://www.w3.org/2001/XMLSchema#string

Rudiger Hehlmann

http://www.w3.org/2001/XMLSchema#string

Susanne Saussele

http://www.w3.org/2001/XMLSchema#string

P304

686-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-12-319038

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Gianantonio Rosti

Michele Baccarani

P577

2011-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21536864

http://www.w3.org/2001/XMLSchema#string